AEGON ASSET MANAGEMENT UK Plc Cuts Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• AEGON ASSET MANAGEMENT UK Plc reduced its holdings in Gilead Sciences by 11.4% in Q2, owning 253,229 shares valued at approximately $28 million after selling 32,588 shares.
• Other institutional investors have increased their stakes, with One Wealth Advisors LLC growing its position by 34.8% during the same quarter.
• Gilead Sciences reported strong Q2 earnings with a net revenue of $7.08 billion, exceeding estimates, and declared a quarterly dividend of $0.79.

AEGON ASSET MANAGEMENT UK Plc lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,229 shares of the biopharmaceutical company's stock after selling 32,588 shares during the period. AEGON ASSET MANAGEMENT UK Plc's holdings in Gilead Sciences were worth $28,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. One Wealth Advisors LLC grew its stake in Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock valued at $1,016,000 after purchasing an additional 2,364 shares during the last quarter. Ariel Investments LLC grew its stake in shares of Gilead Sciences by 7.7% during the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after acquiring an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 109 shares during the last quarter. Covea Finance grew its stake in shares of Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock worth $5,732,000 after acquiring an additional 21,200 shares during the last quarter. Finally, Swedbank AB grew its stake in shares of Gilead Sciences by 0.8% during the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock worth $237,393,000 after acquiring an additional 16,663 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $118.48 on Wednesday. The business's 50 day moving average price is $114.84 and its 200 day moving average price is $110.35. The firm has a market cap of $147.01 billion, a P/E ratio of 23.60, a P/E/G ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 52 week low of $84.80 and a 52 week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Rothschild & Co Redburn boosted their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada upped their target price on Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $118.08.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,000 shares of company stock valued at $7,632,100. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.